Related Experiment Video
Updated: Aug 13, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks
Published on: March 17, 2023
Pharmacokinetics of liposomal amphotericin B during extracorporeal albumin dialysis
Helene Vogelsinger1, Michael Joannidis, Jordan Kountchev
1Clinical Pharmacokinetics Unit, Innsbruck Medical School, Innsbruck, Austria.
Abstract:
Extracorporeal blood purification techniques such as hemofiltration or albumin dialysis can exert a significant, but not easily predictable influence on plasma pharmacokinetics of antimicrobial agents. The effect of albumin dialysis on the pharmacokinetics of liposomal amphotericin B (AMB) and other lipid-formulated drugs has not been investigated so far. Therefore, plasma concentrations of liberated and liposomal AMB were measured in a patient, who obtained liposomal AMB for suspected invasive mycosis and required albumin dialysis because of cholestatic liver failure caused by graft versus host disease after bone marrow transplantation. Liberated and liposomal AMB were separated by solid phase extraction and measured by high performance liquid chromatography. No excessive AMB elimination took place during albumin dialysis. Plasma levels of liposomal AMB exceeded those of liberated AMB. Pharmacokinetic data were comparable to those obtained previously in patients on hemofiltration and in critically ill patients without extracorporeal blood purification.
Insights
Albumin dialysis did not significantly alter liposomal amphotericin B levels in a patient with invasive mycosis. Plasma concentrations of liposomal amphotericin B remained higher than liberated forms during treatment.
Area of Science:
- Pharmacology
- Nephrology
- Oncology
Background:
- Extracorporeal blood purification techniques can unpredictably affect antimicrobial pharmacokinetics.
- The impact of albumin dialysis on lipid-formulated drugs, specifically liposomal amphotericin B (AMB), remains unstudied.
Observation:
- Plasma concentrations of liposomal and liberated AMB were measured in a patient undergoing albumin dialysis for cholestatic liver failure post-bone marrow transplant.
- The patient received liposomal AMB for a suspected invasive fungal infection.
Findings:
- Albumin dialysis did not lead to excessive elimination of AMB.
- Plasma levels of liposomal AMB were consistently higher than liberated AMB.
- Pharmacokinetic data were similar to those observed in patients undergoing hemofiltration or without extracorporeal blood purification.
Implications:
- Albumin dialysis appears to be a safe method for AMB administration in patients requiring both treatments.
- Further research is warranted to confirm these findings in a larger patient cohort.
- Understanding drug-specific interactions with extracorporeal therapies is crucial for optimizing patient care.
More Related Videos
10:53Anionic Polymerization of an Amphiphilic Copolymer for Preparation of Block Copolymer Micelles Stabilized by π-π Stacking Interactions
Published on: October 10, 2016
08:44Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes
Published on: July 30, 2020
Related Concept Videos
Estimation of k and VD of Aminoglycosides
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Antifungal Agents
Drug Distribution: Plasma Protein Binding
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis